Biomea Fusion, Inc. (BMEA)
NASDAQ · Manufacturing · Pharmaceutical preparations
BMEA price, last 12 months
Key stats
- Previous close
- $1.49
- Open
- $1.49
- Day range
- $1.30 – $1.49
- 52-week range
- $0.8719 – $2.99
- Volume
- 3.1M
- Avg volume (20 days)
- 2.3M
- Market cap
- $95.7M
Performance
Technicals and fundamentals
About Biomea Fusion, Inc.
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $95.7M